NSIM
BIB icon

North Star Investment Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

North Star Investment Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-150
Closed -$8K – 438
2019
Q1 		$8K Hold
150
– – ﹤0.01% 853
2018
Q4 		$6K Hold
150
– – ﹤0.01% 871
2018
Q3 		$10K Hold
150
– – ﹤0.01% 838
2018
Q2 		$9K Hold
150
– – ﹤0.01% 868
2018
Q1 		$8K Hold
150
– – ﹤0.01% 869
2017
Q4 		$8K Buy
+150
New +$8.46K ﹤0.01% 851

Other funds holding BIB

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

North Star Investment Management's BIB Position: Q2 2019 in Review

North Star Investment Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2019, closing a stake of 150 shares — an estimated $8K sold.

North Star Investment Management first reported a position in BIB in Q4 2017 and held it in 6 quarters. The position peaked at $10K in Q3 2018. 34 funds tracked by Wall St. Rank hold BIB as of Q2 2019.

  • North Star Investment Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2019 after selling out during the quarter.
  • North Star Investment Management sold 150 ProShares Ultra NASDAQ Biotechnology shares in Q2 2019, an estimated $8K.
  • North Star Investment Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2017 and held it in 6 quarters.
  • North Star Investment Management's ProShares Ultra NASDAQ Biotechnology position peaked at $10K in Q3 2018.
  • 34 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2019.

Based on North Star Investment Management's 13F filing for Q2 2019, filed 15 Jul 2019.